CD4 and tuberculosis: Cohort(s): randomized, observer blind, Phase I/II trial of HIV-infected adults from Switzerland on ART; No history of TB disease, CD4 >200, BCG-immunized (73%), Mtb-infected (QFT+, 3%)Immunization: M72 in AS01E i.m. (+0, +1 month; n = 22)AS01E i.m. (+0, +1 month; n = 8)Saline i.m. (+0, +1 month; n = 7)